Millie Capital Management LLC Increases Stake in Celgene Corporation (CELG)

Millie Capital Management LLC raised its stake in shares of Celgene Corporation (NASDAQ:CELG) by 0.4% during the first quarter, Holdings Channel reports. The institutional investor owned 30,670 shares of the biopharmaceutical company’s stock after buying an additional 136 shares during the period. Celgene Corporation accounts for approximately 3.6% of Millie Capital Management LLC’s investment portfolio, making the stock its 6th largest position. Millie Capital Management LLC’s holdings in Celgene Corporation were worth $3,816,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Motco boosted its stake in Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 620 shares in the last quarter. Carroll Financial Associates Inc. boosted its stake in Celgene Corporation by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 400 shares in the last quarter. Oakworth Capital Inc. boosted its stake in Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 412 shares in the last quarter. Reilly Financial Advisors LLC boosted its stake in Celgene Corporation by 15.3% in the first quarter. Reilly Financial Advisors LLC now owns 1,211 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 161 shares in the last quarter. Finally, WealthTrust Arizona LLC boosted its stake in Celgene Corporation by 26.1% in the first quarter. WealthTrust Arizona LLC now owns 1,213 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 251 shares in the last quarter. 78.26% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Shares of Celgene Corporation (NASDAQ:CELG) opened at 125.16 on Tuesday. The stock’s 50 day moving average price is $119.14 and its 200 day moving average price is $119.67. Celgene Corporation has a one year low of $94.42 and a one year high of $127.64. The company has a market cap of $97.73 billion, a PE ratio of 47.00 and a beta of 1.82.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.21. Celgene Corporation had a return on equity of 70.94% and a net margin of 18.32%. The company had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3.04 billion. During the same quarter in the previous year, the firm earned $1.32 EPS. Celgene Corporation’s revenue was up 17.8% on a year-over-year basis. Equities analysts predict that Celgene Corporation will post $7.29 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/2654458/millie-capital-management-llc-increases-stake-in-celgene-corporation-celg.html.

Several equities research analysts have recently weighed in on the company. Jefferies Group LLC set a $154.00 price objective on Celgene Corporation and gave the company a “buy” rating in a research report on Saturday, May 13th. Oppenheimer Holdings, Inc. set a $148.00 price objective on Celgene Corporation and gave the company a “buy” rating in a research report on Wednesday, June 14th. BidaskClub raised Celgene Corporation from a “strong sell” rating to a “sell” rating in a research report on Wednesday, June 14th. Cowen and Company reissued an “outperform” rating and issued a $150.00 price objective on shares of Celgene Corporation in a research report on Wednesday, March 8th. Finally, Mizuho increased their price objective on Celgene Corporation from $130.00 to $134.00 and gave the company a “buy” rating in a research report on Thursday, June 1st. Two research analysts have rated the stock with a sell rating, five have given a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $139.49.

In other Celgene Corporation news, insider Rupert Vessey sold 4,785 shares of the company’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the transaction, the insider now owns 4,004 shares of the company’s stock, valued at approximately $481,200.72. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director James J. Loughlin sold 9,250 shares of the company’s stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $124.00, for a total value of $1,147,000.00. Following the completion of the transaction, the director now directly owns 32,169 shares of the company’s stock, valued at approximately $3,988,956. The disclosure for this sale can be found here. Insiders have sold a total of 28,068 shares of company stock valued at $3,459,768 in the last three months. 0.95% of the stock is owned by insiders.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:CELG”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.